Oral treatment of visceral leishmaniasis with miltefosine

By Sundar S.   Gupta L. B.   Makharia M. K.   Singh M. K.   Voss A.   Rosenkaimer F.   Engel J.   Murray H. W.  

Annals of Tropical Medicine and Parasitology, Vol. 93, Iss. 6, 1999-09 ,pp. : 589-597

Routledge Ltd

Access to resources Recommend Favorite

Miltefosine in the treatment of a case of visceral leishmaniasis with renal dysfunction

By Kumar N.   Pandey K.   Das V. N. R.   Sinha P. K.   Topno R. K.   Verma N.   Lal C. S.   Das P.   Bhattacharya S. K.  

Annals of Tropical Medicine and Parasitology, Vol. 101, Iss. 7, 2007-10 ,pp. : 649-651

Maney Publishing

Access to resources Recommend Favorite

BN 52021 (a platelet activating factor-receptor antagonist) decreases alveolar macrophage-mediated lung injury in experimental extrinsic allergic alveolitis

By Perez-Arellano J-L.   Marton T.   Lopez-Novoa J-M.   Sanchez M-L.   Montero A.   Jimenez A.  

Mediators of Inflammation, Vol. 7, Iss. 3, 1998-06 ,pp. : 201-210

Informa Healthcare

Access to resources Recommend Favorite

Successful treatment of visceral leishmaniasis with fluconazole and allopurinol in a patient with renal failure

By Colakoglu Murat   Fidan Yaylali Guzin   Yalcin Colakoglu Nagihan   Yilmaz Mustafa  

Scandinavian Journal of Infectious Diseases, Vol. 38, Iss. 3, 2006-03 ,pp. : 208-210

Informa Healthcare

Access to resources Recommend Favorite

Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients

By Marques Nuno   Sa Rosa   Coelho Filomena   Oliveira Joaquim   Saraiva Da Cunha J.   Melico-Silvestre A.  

Scandinavian Journal of Infectious Diseases, Vol. 40, Iss. 6-7, 2008-01 ,pp. : 523-526

Informa Healthcare

Access to resources Recommend Favorite